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Delay in the delivery of treatment for gynaecological
cancers has been previously investigated.1 2 In some
cases, the delay reflects the illness behaviour of women;
in others, it was inherent in the system for delivering
health care. Few studies have linked delay in treatment
with survival, although a study from Israel found that
survival from endometrial cancer was not affected by a
delay in treatment of four months.3
We investigated links between delays in treatment
and survival, using a recently completed audit of
endometrial cancer treatment in Scotland.
Methods and results
We collected data from the case notes of all women
resident in Scotland who were diagnosed between 1
January 1996 and 31 December 1997 as having
endometrial carcinoma. Of 781 cases, we found case
notes for 714, and, out of these, we analysed the 703
cases that involved operative treatment.
We calculated time intervals from the dates of gen›
eral practitioner referral letters, clinic appointments,
investigations, and operations. We allocated an
International Federation of Gynaecology and Obstet›
rics (FIGO) stage to each case retrospectively4; we then
categorised cases by FIGO stage.5 We linked these data
to survival information from ISD›Scotland and did a
univariate analysis using the Kaplan›Meier method
and multivariate analysis using Cox’s proportional
hazards analysis.
Delay and survival were inversely related: women
with the shortest delay had more advanced disease and
survival was least likely for these patients (table). This
trend is seen most starkly in the delay from general
practitioner referral to first hospital visit.
The median interval from referral to definitive
operation was 62 days (90th centile 150 days). Large
variations between health board areas existed: the
median interval from referral to definitive operation
varied from 46 to 81 days (74 to 287 days).
Comment
The interaction between survival and delay in
treatment is complex: we found that patients who
experience the longest delay in treatment are more
likely to survive. This is paradoxical: it is popularly
assumed that delay has a significant and harmful
impact on survival.
This interaction is partially accounted for by the
relation between stage and delay but is only partly
explained by the FIGO stage category in a Cox
proportional hazards model corrected for age, stage,
and use of radiotherapy.
The traditional view is that delay caused by organi›
sational defects has an adverse effect on the disease:
this influences survival. Our study suggests that disease
influences delay, and so delay is a confounding factor.
The fact that the strongest effect between delay and
survival is seen in the interval between referral and the
first hospital visit suggests that general practitioners
communicate information related to presentation in
some way to consultants. This communication ensures
that consultants respond faster to patients who are at
higher risk. Consultants seem to be able, from first
clinic visit, to differentiate patients at greater risk and to
ensure that cancer is diagnosed and treated faster.
Women with the longest delays have the best survival,
and vice versa, suggesting that the “healing art”
remains an important but elusive factor.
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Interval from general practitioner referral to surgery and survival
No
Hazard ratio (95% CI)
Univariate analysis Multivariate analysis
GP to surgery interval:
<40 days 154 1 1
40›61 days 155 0.50 (0.30 to 0.82) 0.71 (0.43 to 1.19)
62›91 days 155 0.34 (0.19 to 0.59) 0.47 (0.27 to 0.83)
>92 days 153 0.39 (0.23 to 0.67) 0.53 (0.30 to 0.93)
Age:
<60 years 135 1 1
>60 years 545 1.83 (1.06 to 3.16) 1.28 (0.72 to 2.30)
FIGO stage category:
1AG1 and 1BG1 (low risk) 182 1 1
1AG2/3, 1BG2/3, and 1CG1/2
(intermediate risk)
289 3.11 (1.38 to 7.01) 2.8 (1.15 to 6.85)
1CG3, stages 2/3/4 (high risk) 182 12.8 (5.9 to 27.9) 11.1 (4.74 to 25.8)
Cannot be assigned to case 50 5.8 (2.2 to 15.2) 5.2 (1.85 to 14.7)
Adjuvant radiotherapy:
Yes 275 1 1
No 428 0.83 (0.57 to 1.19) 2.00 (1.29 to 3.11)
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